Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Burdock Root

VaxInnate Reports Positive Results From Preclinical Testing Of Swine Flu Vaccine Developed Using Novel Technology
VaxInnate Corporation today reported positive preclinical results for a recombinant swine flu vaccine it developed in less than three weeks, making it one of the first companies in the world to begin testing a vaccine that could help halt the spread of the swine flu pandemic.
generic viagra online
Sound Imaging: Clever Acoustics Help Blind People See The World
Video from portable cameras is analysed to calculate the distance of obstacles and predict the movements of people and cars. This information is then transformed and relayed to a blind person as a three-dimensional "picture" of sound.
News of the day
Kenya Seeks Support From PEPFAR To Expand Blood Transfusion Centers
Kenya"s Medical Services Permanent Secretary James Ole Kiyiapi announced Thursday that the government is in negotiations with PEPFAR for support in building additional blood transfusion centers in the country, Capital News reports. In an opening address at the 5th International Africa Society for Blood Transfusion, Ole Kiyiapi said the government estimates it will cost about Sh230 million ($2.99 million) to build the new centers and train appropriate staff.
Sexual Health

Polymorphism In Endostatin, An Angiogenesis Inhibitor, And Prostate Cancer Risk And Survival: A Prospective Study

UroToday.com - Angiogenesis is the process of new blood vessel formation in tumors, facilitating their growth. Endostatin is a cleavage product of collagen and is a potent inhibitor of endothelial cell proliferation and migration. Endostatin causes apoptosis in endothelial and tumor cells. Prostate cancer expresses angiogenic factors. A missense mutation in the coding region for endostatin has been described, but the polymorphism affects protein conformation rather than protein expression. Cellular assays suggested that the result is impaired endostatin binding to laminin, a basement membrane protein. In an online article in the International Journal of Cancer, Dr. Lorelei Mucci and colleagues present data from the Physicians" Health Study examining the D104N endostatin polymorphism in relation to prostate cancer risk and survival. The Physicians" Health Study was a randomized trial of aspirin and beta-carotene supplementation among 22,071 physicians ages 40-84 that was initiated in 1982. A total of 14,916 participants had samples available for this nested case-control study. The analysis identified 544 incident prostate cancer cases and 678 controls for polymorphism genotyping. Among the control men, 84.2% were wildtype homozygous (DD), 14.5% were heterozygous (DN), and 1.3% were homozygous carriers of the rare allele (NN). Carriage of the polymorphic N allele was not associated with risk of total prostate cancer risk. There was no evidence that the endostatin D104N polymorphism was associated with prostate cancers diagnosed at a younger or older age. There was also no association between carriage of the N allele and development of lethal prostate cancer. Participants whose prostate cancer contained the polymorphic allele were less likely to be overweight or obese (26%) compared to men with the DD genotype (47.8%). This large study observed no overall association between the D104N endostatin polymorphism and prostate cancer risk or prognosis. Mucci LA, Stark JR, Figg WD, Schumacher F, Li H, Abe M, Hennessy K, Stampfer MJ, Gaziano JM, Ma J, Kantoff PW Int J Cancer. 2009 Mar 11. (Epub ahead of print) 10.1002/ijc.24423 Written by UroToday.com Contributing Editor Christopher P. Evans, MD, FACS UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice. To access the latest urology news releases from UroToday, go to: www.urotoday.com Copyright © 2009 - UroToday


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009